01 NPHLA Intelligence desk
For weight-loss clinics, med spas, pharmacists, prescribers, medical directors and metabolic-health operators: what is changing in GLP-1 and next-generation obesity medicine — and what it could mean for your practice.
Featured on this desk
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
NPHLA tracked 29 new official records on this desk today: 20 trial updates, 9 new studies.
Automated from official records13 sources1 min read
Nothing in this view yet. New briefings appear as the desk publishes them.
Phase 2, The Methodist Hospital Research Institute. Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight. I…
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
